C. Thang

Efficacy and safety of imeglimin add‐on to insulin monotherapy in Japanese patients with type 2 diabetes (TIMES 3): A randomized, double‐blind, placebo‐controlled phase 3 trial with a 36‐week open‐label extension period

H. Watada, Caroline Reilhac, J. Dubourg, 2021, Diabetes, obesity & metabolism.

Efficacy and Safety of Imeglimin Monotherapy Versus Placebo in Japanese Patients With Type 2 Diabetes (TIMES 1): A Double-Blind, Randomized, Placebo-Controlled, Parallel-Group, Multicenter Phase 3 Trial

K. Ueki, J. Dubourg, J. Grouin, 2021, Diabetes Care.

Phase 2 trial with imeglimin in patients with Type 2 diabetes indicates effects on insulin secretion and sensitivity

G. Pacini, A. Mari, V. Pīrāgs, 2022, Endocrinology, diabetes & metabolism.

Bioavailability of a Co-formulated Combination of Amodiaquine and Artesunate under Fed and Fasted Conditions

J. Barré, S. Fitoussi, A. Filali-Ansary, 2009, Arzneimittelforschung.

Evaluation of PXL065 - Deuterium-Stabilized (R)-Pioglitazone in NASH Patients: a Phase 2 randomized placebo-controlled trial (DESTINY-1).

K. Cusi, P. Bedossa, D. Moller, 2023, Journal of hepatology.